Home › Compare › EMYIF vs ABBV
EMYIF yields 16.13% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 7
Combined, EMYIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EMYIF + ABBV for your $10,000?
Euromoney Institutional Investor PLC, together with its subsidiaries, provides business-to-business information services in the United Kingdom, North America, and internationally. The company operates through three segments: Fast Markets, Financial & Professional Services, and Asset Management. The Fast Market segment provides commodity price benchmarks and analysis to its clients' business processes and workflows in the metals, mining, forest products, and agriculture industries. The Financial & Professional Services segment offers actionable data, market and people intelligence, accreditation, marketing, and event services to financial and professional services businesses. The Asset Management segment provides independent research that enables its customers to make informed investment decisions; runs networks and conferences that bring asset allocators and managers together; and offers news and data for the industry to stay informed and make deals. It also engages in the research and data service, publishing, property holding activities. The company was formerly known as Euromoney Publications PLC and changed its name to Euromoney Institutional Investor PLC in April 1999. The company was incorporated in 1969 and is headquartered in London, the United Kingdom. As of November 24, 2022, Euromoney Institutional Investor PLC was taken private.
Full EMYIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.